会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Process for the preparation of nitrobenzene derivatives
    • 硝基苯衍生物的制备方法
    • US5719317A
    • 1998-02-17
    • US809778
    • 1997-03-28
    • Franco Manfre
    • Franco Manfre
    • B01J23/44C07B61/00C07C201/12C07C205/55C07C205/56C07C205/00
    • C07C201/12
    • A method for preparing a compound of formula (I), wherein R.sub.1 and R.sub.2, which are the same or different, are a hydrogen atom or an alkyl or alkoxy radical, or R.sub.1 and R.sub.2, taken together with the carbon atom to which they are attached, form a cycloalkyl radical containing 3-6 carbon atoms. The method comprises dehalogenating a derivative of formula (lI), wherein R.sub.1 and R.sub.2 have the same meanings as in formula (1) and Hal is a chlorine or bromine atom, using 1-2 mol of triethylammonium formate, in the presence of 0.002-0.1 mol of coal-borne palladium per mol of the compound of formula (II), in aceonitrile or tetrahydrofuran and at a temperature between 50.degree. C. and the boiling point of the reaction medium. ##STR1##
    • PCT No.PCT / FR95 / 01241 Sec。 371日期1997年3月28日 102(e)1997年3月28日PCT PCT 1995年9月27日PCT公布。 出版物WO96 / 日期:1996年4月4日制备式(I)化合物的方法,其中R1和R2相同或不同,为氢原子或烷基或烷氧基,或R1和R2与碳一起 它们所连接的原子形成含有3-6个碳原子的环烷基。 该方法包括使式(I)的衍生物脱卤,其中R1和R2具有与式(1)中相同的含义,Hal是氯或溴原子,使用1-2摩尔的三乙基铵甲酸酯,在0.002- 每摩尔式(II)化合物,在乙腈或四氢呋喃中,在50℃和反应介质的沸点之间的温度下,0.1摩尔的煤炭钯。 (I)(II)
    • 9. 发明授权
    • 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives,
preparation thereof, intermediates thereof and drugs containing the same
    • 5H,10H-咪唑并[1,2-a]茚并[1,2-e]吡嗪-4-酮衍生物,其制备方法,其中间体和含有它们的药物
    • US5990108A
    • 1999-11-23
    • US101428
    • 1998-07-09
    • Jean-Claude AloupJean BouquerelDominique DamourJean-Claude HardyPatrick JimonetFranco ManfreSerge MignaniPatrick Nemecek
    • Jean-Claude AloupJean BouquerelDominique DamourJean-Claude HardyPatrick JimonetFranco ManfreSerge MignaniPatrick Nemecek
    • A61K31/00A61K31/495A61K31/4985A61K31/675A61P1/00A61P1/14A61P25/00A61P29/00A61P43/00C07D233/90C07D235/00C07D487/04C07F9/6561
    • C07D487/04C07F9/6561
    • Compounds of formula (I), wherein R is a hydrogen atom or a --COOH, -alk-COOH, --PO.sub.3 H.sub.2, --CH.sub.2 --PO.sub.3 H.sub.2, or --CH.dbd.CH--COOH radical, or a phenyl radical substituted by a carboxy radical, R.sub.1 is an alk-CN, -alk-COOH, -alk-Het, alk-PO.sub.3 H.sub.2 or -alk-CO--NH--SO.sub.2 R.sub.2 radical, R.sub.2 is an alkyl or phenyl radical, alk is an alkyl radical, Het is a saturated or unsaturated mono- or polycyclic heterocyclic ring containing 1-9 carbon atoms and one or more heteroatoms selected from O, S and N, said heterocyclic ring optionally being substituted by one or more alkyl, phenyl or phenylalkyl radicals, with the proviso that when R is a hydrogen atom or a --COOH or --PO.sub.3 H.sub.2 radical, R.sub.1 cannot be -alk-COOH, isomers, racemic mixtures, enantiomers and diastereoisomers thereof, salts thereof, the preparation thereof, intermediates thereof and drugs containing said compounds, are disclosed. The compounds of formula (I) have valuable pharmacological properties and are antagonists of the .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor also known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive antagonists of the N-methyl-D-aspartate (NMDA) receptor, and specifically ligands for NMDA receptor glycine modulator sites. ##STR1##
    • PCT No.PCT / FR97 / 00019 Sec。 371日期:1998年7月9日 102(e)日期1998年7月9日PCT 1997年1月6日PCT PCT。 出版物WO97 / 25328 日期:1997年7月17日式(I)化合物其中R为氢原子或-COOH,-alk-COOH,-PO3H2,-CH2-PO3H2或-CH = CH-COOH基,或苯基取代 通过羧基,R 1是烷基-C CN,-alk-COOH,-alk-Het,alk-PO 3 H 2或-alk -CO-NH-SO 2 R 2基团,R 2是烷基或苯基, Het是含有1-9个碳原子和一个或多个选自O,S和N的杂原子的饱和或不饱和单环或多环杂环,所述杂环任选被一个或多个烷基,苯基或苯基烷基取代,其中 条件是当R是氢原子或-COOH或-PO 3 H 2基团时,R 1不能是-alk COOH,其异构体,外消旋混合物,对映异构体和非对映异构体,其盐,其制备,其中间体和含有所述化合物的药物, 被披露。 式(I)化合物具有有价值的药理学性质,也是也称为quisqualate受体的α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)受体的拮抗剂。 此外,式(I)化合物是N-甲基-D-天冬氨酸(NMDA)受体的非竞争性拮抗剂,特别是NMDA受体甘氨酸调节剂位点的配体。